Search - tctmd.com

Displaying 61 - 68 of 68

Sort: Relevancy | Date

News Conference News ACC 2014

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Jason Kahn

March 31, 2014

News Conference News ACC 2014

Massachusetts Study Sees Steep Declines in Revascularization Over Last Decade

L.A. McKeown

March 30, 2014

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

Yael L. Maxwell

March 27, 2012

Video

» Interview

METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance In Patients with Chronic Heart Failure and Reduced Ejection Fraction

May 4, 2022

Video

» Interview

ACC 2022: DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications for Heart Failure with Reduced Ejection Fraction

April 3, 2022

Video

» Interview

ACC 2019: PANACHE: Safety and Efficacy of Neladenoson Bialanate, a Partial Adenosine A1 Receptor Agonist, in Patients with Heart Failure and Preserved Ejection Fraction: Results from the PANACHE Randomized Controlled Trial

March 18, 2019

Advertisement

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Massachusetts Study Sees Steep Declines in Revascularization Over Last Decade

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance In Patients with Chronic Heart Failure and Reduced Ejection Fraction

ACC 2022: DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications for Heart Failure with Reduced Ejection Fraction

ACC 2019: PANACHE: Safety and Efficacy of Neladenoson Bialanate, a Partial Adenosine A1 Receptor Agonist, in Patients with Heart Failure and Preserved Ejection Fraction: Results from the PANACHE Randomized Controlled Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content